Valneva

Valneva SE is a European specialty vaccine company established in 2013 through the merger of Intercell AG and Vivalis SA. Headquartered in Saint-Herblain, France, it has operational sites in Vienna, Austria, and manufacturing facilities in Scotland, Sweden, and Vienna. The company also has offices in Canada and the United States. Valneva is dedicated to developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Its commercial portfolio includes three approved vaccines: IXIARO®/JESPECT® for Japanese encephalitis, IXCHIQ® for Chikungunya, and a cholera vaccine. The company is also advancing several vaccine candidates, including VLA15, the only Lyme disease vaccine in advanced clinical trials. Valneva targets markets with substantial commercial opportunities, particularly in travel vaccines and vector-borne diseases, and aims to contribute to global public health by addressing vaccine-preventable diseases.